Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.
Greenbaum LA, et al. Among authors: henning p.
Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.
Kidney Int. 2016.
PMID: 26880462
Free article.
Clinical Trial.